FDA support advances biomarker for earlier, more precise Parkinson's clinical trials

The Critical Path Institute (C-Path) has published "Regulatory endorsement for the exertion of alpha-synuclein effect amplification assay (αSyn-SAA) arsenic a susceptibility and hazard biomarker for objective trials targeting synucleinopathies" successful the Journal of Parkinson's Disease, marking a important milestone for its Critical Path for Parkinson's consortium. The findings item scientific, regulatory and collaborative efforts culminating successful a U.S. Food and Drug Administration (FDA) biomarker Letter of Support for this work.